Aurora Kinase A

An aurora kinase that localizes to the CENTROSOME during MITOSIS and is involved in centrosome regulation and formation of the MITOTIC SPINDLE. Aurora A overexpression in many malignant tumor types suggests that it may be directly involved in NEOPLASTIC CELL TRANSFORMATION.

Also Known As:

Networked: 1061 relevant articles (49 outcomes, 187 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Liu, Quentin: 19 articles (01/2022 - 08/2009)
2.	El-Rifai, Wael: 17 articles (03/2022 - 04/2008)
3.	Ecsedy, Jeffrey: 16 articles (10/2019 - 11/2008)
4.	Sen, Subrata: 16 articles (12/2016 - 03/2003)
5.	Venkatakrishnan, Karthik: 15 articles (01/2020 - 02/2011)
6.	Zhou, Xiaofei: 15 articles (01/2020 - 10/2012)
7.	Ecsedy, Jeffrey A: 14 articles (03/2017 - 03/2007)
8.	Golemis, Erica A: 11 articles (08/2020 - 09/2010)
9.	Zhou, Shu-Feng: 11 articles (12/2017 - 01/2015)
10.	Belkhiri, Abbes: 11 articles (07/2017 - 04/2008)

Related Diseases

1.	Neoplasms (Cancer) 06/01/2011 - "Patients with BRCA2-positive and AURKA-negative tumors had higher overall (P=0.001) and disease-free (P=0.001) survival rates than did patients with AURKA-positive and BRCA2-negative tumors. " 08/07/2023 - "BOD1L1 depletion or Aurora kinase A inhibition eliminated resistance to UMK57 in CIN cancer cells. " 05/15/2013 - "NEDD9 depletion destabilizes Aurora A kinase and heightens the efficacy of Aurora A inhibitors: implications for treatment of metastatic solid tumors." 09/02/2010 - "Importantly, apoptosis provoked by Aurk inhibition was p53 independent, suggesting that Aurka/Aurkb inhibitors will show efficacy in treating primary or relapsed malignancies having Myc involvement and/or loss of p53 function." 01/01/2023 - "Our study elucidates the oncogenic role of AURKA and underscores its prognostic value across a spectrum of cancers, including EAC. "
2.	Melanoma (Melanoma, Malignant) 07/01/2023 - "ZNC97018978 is an effective and safe inhibitor of AURKA in vitro; its safety and effectiveness in vivo as a potential treatment for cutaneous melanoma should be further determined." 03/10/2016 - "These findings could bear significant implications for the application and the success of anti-AURKA approaches that have already entered phase-II clinical trials for human melanoma. " 01/01/2023 - "High expression of AURKA implied poor survival in melanoma patients. " 01/01/2023 - "Various targetable aberrations were identified, such as AURKA and ERBB2, in mucosal and acral melanomas, respectively. " 01/01/2018 - "However, the status and the clinical significance of AURKA copy number (CN) in acral melanoma (AM) have not been fully elucidated. "
3.	Neuroblastoma 10/01/2018 - "Preclinical and early-phase clinical studies of BRD4 and AURKA inhibitors, however, show limited efficacy against neuroblastoma when used alone. " 02/05/2023 - "With this, our SAR-study provides interesting lead structures for further optimization and validation of AURKA degradation as a potential therapeutic strategy in neuroblastoma." 02/05/2023 - "Targeted AURKA degradation: Towards new therapeutic agents for neuroblastoma." 01/01/2021 - "The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53." 01/01/2021 - "Our data indicate a key role of the binding and cleavage of the AURKA transcript in an MCPIP1-dependent suppressive effect on neuroblastoma cells."
4.	Breast Neoplasms (Breast Cancer) 01/01/2022 - "Our study suggests that RHAMM, AURKA, TPX2, PLK1, and PLK4 can be used as potential targets for treatment or as a prognostic value in breast cancer patients." 12/01/2015 - "Germline variation in AURKA was evaluated for association with breast cancer and intrinsic breast cancer subtypes in the Carolina Breast Cancer Study (CBCS), a population-based case-control study of African Americans (AA) and Caucasians (Cau). " 01/01/2014 - "The AURKA gene rs2273535 polymorphism contributes to breast carcinoma risk - meta-analysis of eleven studies." 01/01/2011 - "When all the studies were pooled into the meta-analysis, there was no evidence showing a significant association between AURKA T91A polymorphism and breast cancer risk (for additive model, OR = 0.839, 95% CI = 0.678-1.038; for dominant model: OR = 0.890, 95% CI = 0.757-1.074; and for recessive model: OR = 0.987, 95% CI = 0.963-1.012). " 01/01/2011 - "Several studies have investigated the associations between AURKA T91A polymorphism and the susceptibility to breast cancer, but the results have been inconclusive. "
5.	Stomach Neoplasms (Stomach Cancer) 11/01/2023 - "This study demonstrates that EBV oncogenic modulators EBNA1 possibly modulate AURKA in EBV-mediated gastric cancer progression." 04/01/2017 - "In the previous study, we identified Aurora-A (AURKA) as the hub gene of the gastric cancer linkage network based genome‑wide association study (eGWAS). " 01/01/2016 - "Our study demonstrated that AURKA rs1047972 TT and (CC + CT) genotypes were significantly associated with an increased risk of gastric cancer. " 10/28/2006 - "In this study, 501 gastric cancer patients and 427 controls were genotyped for two coding SNPs in AURKA, 91A>T (31Ile>Phe) and 169G>A (57Val>Ile). " 09/05/2022 - "circ_0061265 competitively binds to microRNA-885-3p to promote the development of gastric cancer by upregulating AURKA expression."

Related Drugs and Biologics

1.	MLN 8237
2.	Phosphotransferases (Kinase)
3.	Paclitaxel (Taxol)
4.	Aurora Kinase A
5.	Biomarkers (Surrogate Marker)
6.	Small Interfering RNA (siRNA)
7.	Proteins (Proteins, Gene)
8.	Aurora Kinases
9.	Messenger RNA (mRNA)
10.	DNA (Deoxyribonucleic Acid)

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Drug Therapy (Chemotherapy)
4.	Chemoradiotherapy
5.	Immunotherapy